Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/3886
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | AIKAWA, N. E. | - |
dc.contributor.author | TRUDES, G. | - |
dc.contributor.author | CAMPOS, L. M. A. | - |
dc.contributor.author | PEREIRA, R. M. R. | - |
dc.contributor.author | MORAES, J. C. B. | - |
dc.contributor.author | RIBEIRO, A. C. | - |
dc.contributor.author | MIRAGLIA, J. | - |
dc.contributor.author | TIMENETSKY, M. do Carmo S. | - |
dc.contributor.author | BONFA, E. | - |
dc.contributor.author | SILVA, C. A. | - |
dc.date.accessioned | 2014-01-28T22:17:14Z | - |
dc.date.available | 2014-01-28T22:17:14Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | LUPUS, v.22, n.13, p.1394-1398, 2013 | - |
dc.identifier.issn | 0961-2033 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/3886 | - |
dc.description.abstract | Objectives The aim of this study was to evaluate the immunogenicity and safety of the influenza A H1N1/2009 vaccine in children under 9 years old with autoimmune rheumatic diseases (ARD). Methods Thirty-eight ARD patients and 11 healthy children received two doses of non-adjuvanted influenza A/California/7/2009 (H1N1) virus-like vaccine. Subjects were evaluated before and 21 days after vaccination. Seroprotection (SP) and seroconversion (SC) rates, geometric mean titers (GMT) and factor increases (FI) in GMT were calculated. Results Mean ages were comparable between patients and controls. Pre-vaccination SP and GMT were similar in patients and controls (p>0.05). Three weeks after immunization, SP (81.6% vs. 81.8%, p=1.0), SC (81.6% vs. 90.9%, p=0.66), GMT (151.5 vs. 282.1, p=0.26) and the FI in GMT (16.7 vs. 36.3, p=0.23) were similar in patients and controls, with both groups achieving an adequate response, according to the European Medicines Agency and Food and Drug Administration standards. Analysis of the possible factors influencing SC showed no difference in demographic data, leukocyte/lymphocyte counts or immunosuppressant use between seroconverted and non-seroconverted patients (p>0.05). The vaccine demonstrated a satisfactory safety profile in this population. Conclusions Two doses of influenza A H1N1/2009 vaccination induced an effective antibody response and caused adverse events in rare instances, suggesting this vaccine is appropriate and can be recommended for this age group. | - |
dc.description.sponsorship | Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2009/51897-5, 2010/10749-0] | - |
dc.description.sponsorship | Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [300559/2009-7, 301411/2009-3, 302724/2011-7] | - |
dc.description.sponsorship | Federico Foundation | - |
dc.description.sponsorship | Butantan Foundation | - |
dc.description.sponsorship | Nucleo de Apoio a Pesquisa ""Saude da Crianca e do Adolescente"" da USP (NAP-CriAd) | - |
dc.language.iso | eng | - |
dc.publisher | SAGE PUBLICATIONS LTD | - |
dc.relation.ispartof | Lupus | - |
dc.rights | restrictedAccess | - |
dc.subject | Vaccine | - |
dc.subject | pandemic influenza A H1N1 | - |
dc.subject | immunogenicity | - |
dc.subject | rheumatic diseases | - |
dc.subject.other | juvenile idiopathic arthritis | - |
dc.subject.other | systemic-lupus-erythematosus | - |
dc.subject.other | reduced immunogenicity | - |
dc.subject.other | children | - |
dc.subject.other | classification | - |
dc.subject.other | dermatomyositis | - |
dc.subject.other | criteria | - |
dc.title | Immunogenicity and safety of two doses of a non-adjuvanted influenza A H1N1/2009 vaccine in young autoimmune rheumatic diseases patients | - |
dc.type | article | - |
dc.rights.holder | Copyright SAGE PUBLICATIONS LTD | - |
dc.identifier.doi | 10.1177/0961203313505926 | - |
dc.identifier.pmid | 24076765 | - |
dc.subject.wos | Rheumatology | - |
dc.type.category | original article | - |
dc.type.version | publishedVersion | - |
hcfmusp.author.external | TRUDES, G.:Univ Sao Paulo, Pediat Rheumatol Unit, BR-05508 Sao Paulo, Brazil | - |
hcfmusp.author.external | MIRAGLIA, J.:Univ Sao Paulo, Inst Butantan, BR-05508 Sao Paulo, Brazil | - |
hcfmusp.author.external | TIMENETSKY, M. do Carmo S.:Univ Sao Paulo, Inst Adolfo Lutz, BR-05508 Sao Paulo, Brazil | - |
hcfmusp.description.beginpage | 1394 | - |
hcfmusp.description.endpage | 1398 | - |
hcfmusp.description.issue | 13 | - |
hcfmusp.description.volume | 22 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | WOS:000326011800011 | - |
hcfmusp.origem.id | 2-s2.0-84887056840 | - |
hcfmusp.publisher.city | LONDON | - |
hcfmusp.publisher.country | ENGLAND | - |
hcfmusp.relation.reference | Aikawa NE, 2013, SCAND J RHEUMATOL, V42, P34, DOI 10.3109/03009742.2012.709272 | - |
hcfmusp.relation.reference | Aikawa NE, 2012, J RHEUMATOL, V39, P167, DOI 10.3899/jrheum.110721 | - |
hcfmusp.relation.reference | [Anonymous], 1980, ARTHRITIS RHEUM, V23, P581 | - |
hcfmusp.relation.reference | BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706 | - |
hcfmusp.relation.reference | Bridges C B, 2001, MMWR Recomm Rep, V50, P1 | - |
hcfmusp.relation.reference | Caillet C, 2011, EUR J CLIN PHARMACOL, V67, P649, DOI 10.1007/s00228-010-0961-8 | - |
hcfmusp.relation.reference | Dell'Era L, 2012, VACCINE, V30, P936, DOI 10.1016/j.vaccine.2011.11.083 | - |
hcfmusp.relation.reference | EMA. Committee for Proprietary Medicinal Products, 1996, EMA PUBL, VCPMP/BWP/214/96 | - |
hcfmusp.relation.reference | EMA. European Committee for Proprietary Medicinal Products, 2004, EUR COMM PROPR MED P | - |
hcfmusp.relation.reference | Fiore Anthony E., 2010, Morbidity and Mortality Weekly Report, V59, P993 | - |
hcfmusp.relation.reference | Guissa VR, 2012, CLIN EXP RHEUMATOL, V30, P583 | - |
hcfmusp.relation.reference | Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928 | - |
hcfmusp.relation.reference | Mathian A, 2011, ARTHRITIS RHEUM-US, V63, P3502, DOI 10.1002/art.30576 | - |
hcfmusp.relation.reference | McCann LJ, 2007, ARCH DIS CHILD, V92, P366, DOI 10.1136/adc.2006.112805 | - |
hcfmusp.relation.reference | Nolan T, 2010, JAMA-J AM MED ASSOC, V303, P37, DOI 10.1001/jama.2009.1911 | - |
hcfmusp.relation.reference | Ozen S, 2010, ANN RHEUM DIS, V69, P798, DOI 10.1136/ard.2009.116657 | - |
hcfmusp.relation.reference | Petty RE, 2004, J RHEUMATOL, V31, P390 | - |
hcfmusp.relation.reference | Shoenfeld Y, 2011, J AUTOIMMUN, V36, P4, DOI 10.1016/j.jaut.2010.07.003 | - |
hcfmusp.relation.reference | Silva CAA, 2010, REV BRAS REUMATOL, V50, P351, DOI 10.1590/S0482-50042010000400002 | - |
hcfmusp.relation.reference | USFDA. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research, 2007, GUID IND CLIN DAT NE | - |
dc.description.index | MEDLINE | - |
hcfmusp.remissive.sponsorship | Butantan | - |
hcfmusp.remissive.sponsorship | CNPq | - |
hcfmusp.remissive.sponsorship | FAPESP | - |
hcfmusp.remissive.sponsorship | Federico Foundation | - |
hcfmusp.remissive.sponsorship | USP | - |
hcfmusp.remissive.sponsorship | Butantan | - |
hcfmusp.remissive.sponsorship | CNPq | - |
hcfmusp.remissive.sponsorship | FAPESP | - |
hcfmusp.remissive.sponsorship | Federico Foundation | - |
hcfmusp.remissive.sponsorship | USP | - |
hcfmusp.citation.scopus | 16 | - |
hcfmusp.scopus.lastupdate | 2024-03-29 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MCM Artigos e Materiais de Revistas Científicas - HC/ICHC Artigos e Materiais de Revistas Científicas - HC/ICr Artigos e Materiais de Revistas Científicas - LIM/17 Artigos e Materiais de Revistas Científicas - LIM/36 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_AIKAWA_Immunogenicity_and_safety_of_two_doses_of_a_2013.PDF Restricted Access | publishedVersion (English) | 112.43 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.